Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Salvia officinalis methanol extract is a botanical preparation derived from the common sage plant, traditionally utilized in Mediterranean medicine. Research in diet-induced obese mouse models and 3T3-L1 cell lines demonstrates that the extract possesses significant anti-diabetic, anti-inflammatory, and anti-obesity properties. Its primary mechanism of action involves the activation of peroxisome proliferator-activated receptors (PPARs), which leads to improved insulin sensitivity, reduced blood glucose and insulin levels, and the inhibition of lipogenesis in adipocytes. Additionally, the extract modulates the immune response by decreasing pro-inflammatory cytokines such as TNF-α and IL-12 while increasing anti-inflammatory cytokines like IL-10. These effects suggest its potential as a natural alternative or adjunct to pharmaceutical agents like rosiglitazone for managing metabolic syndrome and associated chronic inflammation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on salvia officinalis methanol extract.